ArticleTherapeutic advances in gastroenterology2025
Submucosal fibrosis in large colorectal serrated lesions in cases receiving endoscopic submucosal dissection.
Article in Therapeutic advances in gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Early Rectal Cancer: Diagnostic Challenges and the Role of Endoscopic Intermuscular Dissection Within the Therapeutic Algorithm.Diagnostics (Basel, Switzerland) · 2026Review
- Bowel Bubble Formation with Oral Sulfate Solution for Colonoscopy Bowel Preparation Using Same-Day and Split-Day Regimens: The B-BOSS Study.Diagnostics (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Submucosal fibrosis is a known risk factor for adverse outcomes in colorectal endoscopic submucosal dissection (ESD). However, evidence regarding the presence and impact of fibrosis in colorectal serrated lesions (CSLs) remains limited. Objectives: This study aimed to evaluate the association between CSLs and submucosal fibrosis, and to assess the impact of fibrosis presence on therapeutic outcomes of colorectal ESD. Design: Retrospective cohort study. Methods: We retrospectively reviewed consecutive colorectal ESD cases performed between 2020 and 2024. Only lesions ⩾20 mm were included; cases were classified as CSLs and adenoma + T1 cancer according to histological diagnosis. CSLs included sessile serrated lesions (SSL), traditional serrated adenomas, SSL with dysplasia, and unclassified serrated adenomas. Patient/lesion characteristics, presence of fibrosis, severe fibrosis, and ESD outcomes were assessed. Multivariate analyses, including CSLs' histology, were performed to identify factors associated with the presence of submucosal fibrosis and severe fibrosis. Results: A total of 445 colorectal ESD cases were included, comprising 72 CSLs and 373 adenoma + T1 cancer. CSLs were significantly associated with a lower presence of fibrosis (34.7% and 48.5%, Conclusion: CSLs' histology was negatively correlated with submucosal fibrosis in colorectal ESD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.